Exelixis (EXEL) : Traders are bullish on Exelixis (EXEL) as it has outperformed the S&P 500 by a wide margin of 33.73% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 21.16%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 21.68% in the last 1 week, and is up 37.06% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Exelixis (NASDAQ:EXEL): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $11.15 and $10.58 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $11.47. The buying momentum continued till the end and the stock did not give up its gains. It closed at $11.17, notching a gain of 0.90% for the day. The total traded volume was 8,781,667 . The stock had closed at $11.07 on the previous day.
The stock has recorded a 20-day Moving Average of 27.77% and the 50-Day Moving Average is 41.15%. Exelixis, Inc. is up 133.19% in the last 3-month period. Year-to-Date the stock performance stands at 98.05%.
Exelixis (EXEL) : The highest level Exelixis (EXEL) is projected to reach is $12 for the short term and the lowest estimate is at $5. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $9.67 and the possibility the share price can swing is $4.04.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).